Advanced Cancer Therapeutics

Advanced Cancer Therapeutics, LLC engages in the discovery, development, manufacture, and commercialization of cancer therapeutics.

Advanced Cancer Therapeutics, LLC engages in the discovery, development, manufacture, and commercialization of cancer therapeutics. It develops a pipeline of anti-cancer products, including MIF, a macrophage migration inhibitory factor; PU27, a synthetic oligonucleotide that is used as an anticancer compound; PFKFB3, a small molecule compound; CK37, a small molecule that inhibits cell proliferation, choline kinase enzymatic activity, and tumor growth; and a vaccine for human papilloma virus, which is caused for cervical cancer. The company was founded in 2007 and is based in Louisville, Kentucky.